pancreatic cancer
Conditions
Interventions
None listed
Sponsors
Hokkaido University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Unresectable locally advanced pancreatic cancer has been diagnosed by chest CT and abdominal contrast CT. 2. Invasive pancreatic ductal carcinoma (adenocarcinoma, adenosquamous carcinoma, mucinous carcinoma, anaplastic carcinoma) has been diagnosed by histological or cytological examination. 3. Distant metastasis corresponding to M1 is not found on the image. d. First-line treatment (no history of treatment for pancreatic cancer). e. The age of registration date is 20 years or older. f. Written consent of the individual or his / her representative has been obtained for participation in the study.
Exclusion criteria
Exclusion criteria: 1. Your physician determines that you are unsuitable for enrollment in the study. 2. Contrast-enhanced CT imaging is not possible due to drug allergy to iodine-based contrast media. However, contrast-enhanced CT imaging is not possible with steroid prophylactic administration. 3. Pleural effusion and ascites for which metastasis cannot be ruled out are observed on chest CT and abdominal / pelvic contrast CT. 4. Contrast-enhanced MRI shows a liver mass that metastasis cannot be ruled out. 5. Active double cancer (simultaneous double cancer). However, lesions such as carcinoma in situ or intramucosal cancer that are judged to be cured by topical therapy are not included in active double cancer.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| overall survival | — |
Countries
Japan
Contacts
Public ContactMakoto Yoshida
Sapporo Medical University Hospital Department of clinical Oncology
Outcome results
None listed